These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24554298)

  • 1. ADHD Medication Trends in Turkey: 2009-2013.
    Öner Ö; Yilmaz EŞ; Karadağ H; Vural M; Vural EH; Akbulat A; Gürsöz H; Türkçapar H; Kerman S
    J Atten Disord; 2017 Dec; 21(14):1192-1197. PubMed ID: 24554298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
    Štuhec M; Locatelli I; Švab V
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
    Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Shyu YC
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
    Starr HL; Kemner J
    J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study.
    Munasur-Naidoo AP; Truter I
    Int J Clin Pharm; 2019 Aug; 41(4):859-863. PubMed ID: 31313002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, incidence and persistence of ADHD drug use in Japan.
    Okumura Y; Usami M; Okada T; Saito T; Negoro H; Tsujii N; Fujita J; Iida J
    Epidemiol Psychiatr Sci; 2019 Dec; 28(6):692-696. PubMed ID: 29804548
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost of ADHD treatment using methylphenidate and atomoxetine in the South African private healthcare sector.
    Munasur-Naidoo AP; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):677-684. PubMed ID: 31456453
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.
    Treceño C; Martín Arias LH; Sáinz M; Salado I; García Ortega P; Velasco V; Jimeno N; Escudero A; Velasco A; Carvajal A
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):435-41. PubMed ID: 22253017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
    Song I; Lee MS; Lee EK; Shin JY
    Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.